Poor efficacy of anti‐programmed cell death‐1/ligand 1 monotherapy for non‐small cell lung cancer patients with active brain metastases

Abstract

Background The efficacy of anti‐programmed cell death‐1/ligand 1 antibody monotherapy (anti‐PD‐1/PD‐L1 monotherapy) in patients with active brain metastases (BMs) is not established. Here, we aimed to evaluate the efficacy of anti‐PD‐1/PD‐L1 monotherapy in non‐small cell lung cancer (NSCLC) patients with active BMs. Methods This retrospective study included NSCLC patients treated with second‐line or later‐line anti‐PD‐1/PD‐L1 monotherapy between December 2015 and August 2019. Patients were classified into those with or without active BMs, including symptomatic BMs requiring systemic steroids and untreated BMs. The progression‐free survival (PFS) and overall survival (OS) of the patients with and without active BMs were compared. Intracranial and extracranial tumor responses were evaluated in patients with active BMs. Results We analyzed 197 patients who had received anti‐PD‐1/PD‐L1 monotherapy. Among them, 24 had active BMs. Among those without active BMs, 145 had no BMs and 28 had treated asymptomatic BMs. The PFS and OS of patients with active BMs were significantly shorter than those of patients without active BMs (1.3 vs. 2.7 months; P < 0.001, and 4.5 vs. 16.3 months; P = 0.001 respectively). For patients with active BMs, the intracranial and extracranial response rates were 13.3% and 26.7%, respectively. On multivariate analysis, active BMs, poor performance status (PS), and EGFR/ALK positivity were significant factors associated with shorter PFS. Active BMs and poor PS were significant factors associated with shorter OS. Conclusions This study suggested that anti‐PD‐1/PD‐L1 monotherapy was not effective for NSCLC patients with active BMs. Further studies on immunotherapy are needed for patients with active BMs. Key points Significant findings of the study: The present study showed that anti‐PD‐1/PD‐L1 antibody monotherapy was not effective for non‐small cell lung cancer patients with active brain metastases. Intracranial and extracranial response rates were 13.3% and 26.7%, respectively. What this study adds: Further studies on immunotherapy are needed for patients with active BMs.

Efficacy of PD‐1/PD‐L1 inhibitors in patients with non‐small cell lung cancer and brain metastases: A real‐world retrospective study in China

“… 27 The iORR was 62.5% in 11 patients who had not received local radiotherapy, indicating tremendous potentials of ICIs for BM in patients with previously untreated NSCLC and high PD‐L1 expression. However, Tozuka et al 28 showed a poor iORR of 13.3% for anti‐PD‐1/PD‐L1 antibody monotherapy in 15 NSCLC patients with active BM. This may be because of the high proportion of patients with PS >2 (38%) and EGFR or ALK mutations (25%) who may have a low response to immunotherapy.…”

Development of Two Diagnostic Prediction Models for Leptomeningeal Metastasis in Patients With Solid Tumors

“…All predictors were evaluated and recorded when the patient was suspected of LM. Active brain metastases was defined as concomitant untreated or progressed brain metastases ( 14 – 16 ). Progressed extracranial disease means disease progression (limited to extracranial lesions) evaluated by clinicians according to RECIST 1.1 ( 17 ).…”

Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases

“…Considering the heterogeneity of cancer, more research is needed regarding the relationship between BBB permeability and intracranial efficacy of ICIs. Clin Lung Cancer [32] Pembrolizumabbased therapy 0 (0) 0 (0) 3 (42.9) 4 (57.1) 4 (57.1) 3 (42.9) 6 Thorac Cancer [27] PD- Lung Cancer [35] Nivolumab monotherapy 2 (40.0) 0 (0) 0 (0) 3 (60.0) 5 (100.0) 0 (0) 9 Lung Cancer [28] Nivolumab monotherapy…”